Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 20

Sort by

Sort Order Select

Journal Articles

A High-Risk Subgroup Multiple Myeloma Classification Based on the Detection of PR Minor Subclones

Noemie Leblay, Sungwoo Ahn, Sheri Skerget, Rémi Tilmont, Holly Lee, Mansour Poorebrahim, Daniel Penaherrera, Elie Barakat, David Jung, Nizar J Bahlis, Jonathan Keats, Paola Neri

Blood (2023) 142 (Supplement 1): 1941.

https://doi.org/10.1182/blood-2023-189567

Published: 2023

Journal Articles

Herpesvirus Entry Mediator As a Novel Therapeutic Target in Multiple Myeloma

Blood (2023) 142 (Supplement 1): 3296.

https://doi.org/10.1182/blood-2023-190157

Published: 2023

Journal Articles

Prior Immune Effector Cell Therapy, Is Not Associated with an Increased Infectious Risk of Subsequent Bispecific Antibody Therapy for Multiple Myeloma

Lawrence Liu, Scott R. Goldsmith, Sheryl Leahey, Carlos Gomez Luna, Shawn Streeter, Adam Braun, Nitya Nathwani, Michael Rosenzweig, Firoozeh Sahebi, Azra Borogovac, Jonathan Keats, Myo Htut, Arnab Chowdhury, Sanjeet Singh Dadwal, Amrita Krishnan, Murali Janakiram

Blood (2023) 142 (Supplement 1): 1987.

https://doi.org/10.1182/blood-2023-188077

Published: 2023

Journal Articles

Identification of novel mutational drivers reveals oncogene dependencies in multiple myeloma

Blood (2018) 132 (6): 587–597.

https://doi.org/10.1182/blood-2018-03-840132

Published: 2018

Includes: Supplemental data

Journal Articles

Copper 64–labeled daratumumab as a PET/CT imaging tracer for multiple myeloma

Blood (2018) 131 (7): 741–745.

https://doi.org/10.1182/blood-2017-09-807263

Published: 2018

Includes: Multimedia, Supplemental data

Journal Articles

Integrative Analysis of the Genomic Landscape Underlying Multiple Myeloma at Diagnosis: An Mmrf Commpass Analysis

Austin Christofferson, BS, Sara Nasser, Jessica Aldrich, Daniel Penaherrera, Christophe Legendre, Brooks Benard, BS, Sheri Skerget, PhD, The MMRF CoMMpass Network, Jennifer Yesil, MS, Daniel Auclair, PhD, Winnie Liang, PhD, Sagar Lonial, MD, Jonathan Keats, PhD

Blood (2017) 130 (Supplement 1): 326.

https://doi.org/10.1182/blood.V130.Suppl_1.326.326

Published: 2017

Journal Articles

Comprehensive Identification of Fusion Transcripts in Multiple Myeloma: An Mmrf Commpass Analysis

Sara Nasser, Austin Christofferson, BS, Christophe Legendre, Jessica Aldrich, Brooks Benard, BS, The MMRF CoMMpass Network, Jennifer Yesil, MS, Daniel Auclair, PhD, Winnie Liang, PhD, Sagar Lonial, MD, Jonathan Keats, PhD

Blood (2017) 130 (Supplement 1): 61.

https://doi.org/10.1182/blood.V130.Suppl_1.61.61

Published: 2017

Journal Articles

CD33 Is Expressed in a Significant Subset of Multiple Myeloma Patients in the US and May Represent a Viable Therapeutic Target

Moshe Levy, MD, Jonathan Keats, PhD, Sheri Skerget, PhD, Dragan Cicic, MD

Blood (2017) 130 (Supplement 1): 5378.

https://doi.org/10.1182/blood.V130.Suppl_1.5378.5378

Published: 2017

Journal Articles

Adar-Mediated Aberrant a-to-I RNA Editing Is Driven By 1q Amplification and Contributes to Proteasome Inhibitor Resistance in Multiple Myeloma

Alessandro Lagana, PhD, Violetta Leshchenko, PhD, David Melnekoff, BS, MSc, Itai Beno, PhD, Deepak Perumal, PhD, Jonathan Keats, PhD, Mary DeRome, MS, Jennifer Yesil, MS, Daniel Auclair, PhD, Deepu Madduri, MD, Ajai Chari, MD, Hearn Jay Cho, MD PhD, Bart Barlogie, MD PhD, Sundar Jagannath, MD, Joel Dudley, PhD, Samir Parekh, MD

Blood (2017) 130 (Supplement 1): 268.

https://doi.org/10.1182/blood.V130.Suppl_1.268.268

Published: 2017

Journal Articles

Biological and Prognostic Impact of Apobec-Induced Mutations in the Spectrum of Plasma Cell Dyscrasias

Blood (2017) 130 (Supplement 1): 1771.

https://doi.org/10.1182/blood.V130.Suppl_1.1771.1771

Published: 2017

Journal Articles

Transcriptional Plasticity Compensates for Ikaros and Aiolos Proteasomal Degradation and Mediates Resistance to IMiDs in Multiple Myeloma (MM)

Paola Neri, MD, Ines Tagoug, PhD, Ranjan Maity, PhD, Caleb K Stein, MS, Madison Kong, Jonathan Keats, PhD, David Soong, PhD, Christopher Chiu, PhD, P. Leif Bergsagel, MD, Nizar J. Bahlis, MD

Blood (2017) 130 (Supplement 1): 63.

https://doi.org/10.1182/blood.V130.Suppl_1.63.63

Published: 2017

Journal Articles

TRAF3 and TNFAIP3, Two Negative Regulators of NF-Kb Signaling Pathways, Are Mutated in Waldenström’s Macroglobulinemia

Blood (2008) 112 (11): 619.

https://doi.org/10.1182/blood.V112.11.619.619

Published: 2008

Journal Articles

Genomic Complexity and Recurrent Aberration in Multiple Myeloma: Analysis of a Compendium of aCGH and Gene Expression Profiles.

Wee-Joo Chng, Ian Lee, Victor Jimenez-zepeda, Esteban Braggio, Jonathan Keats, Peter Leif Bergsagel, MD, Rafael Fonseca, MD

Blood (2008) 112 (11): 1682.

https://doi.org/10.1182/blood.V112.11.1682.1682

Published: 2008

Journal Articles

Rearrangements of IER3 Represent a Novel and Recurrent Molecular Abnormality in Myelodysplastic Syndromes (MDS)

David P. Steensma, MD, FACP, Jessemy D Neiger, MD, Julie C Porcher, MS, J. Jonathan Keats, PhD, Peter Leif Bergsagel, MD, Ryan A Knudson, Rafael Santana-Davila, MD, Rajiv Kumar, MD, Rhett Ketterling, MD

Blood (2008) 112 (11): 2679.

https://doi.org/10.1182/blood.V112.11.2679.2679

Published: 2008

Journal Articles

Loss of p53 Is a Marker of Progression in Plasma Cell Neoplasias and Is a Negative Prognostic Factor in Relapsed Disease.

Soledad Molnar, MD, Victor J Jimenez Zepeda, Scott Van Wier, Esteban Braggio, Jonathan Keats, Michael Kuehl, Tammy Price-Troska, Greg Ahmann, Rachel Rempel, Kim Henderson, MD, S. Vincent Rajkumar, MD, Philip. R Greipp, MD, Daniel Auclair, John Carpten, Angela Baker, Keith Stewart, MD, P. Leif Bergsagel, MD, Wee Joo Chng, MD, Rafael Fonseca, MD

Blood (2008) 112 (11): 1663.

https://doi.org/10.1182/blood.V112.11.1663.1663

Published: 2008

Journal Articles

Interim Analyses of the MMRC Reference Collection Identifies Recurrent Genomic-Level Events in Multiple Myeloma and Demonstrates That CDKN2C/p18 Deletion Is the Pre-Eminent Copy Number Alteration in Poor Prognosis Disease

Michael A Chapman, Jean-Philippe Brunet, Angela Baker, Jonathan Keats, Gregory Ahmann, BS, Anna C Schinzel, PhD, Anna Moore, Vijayalakshmi Shanmugam, Louise M. Perkins, PhD, Daniel Auclair, PhD, William C. Hahn, M.D., Ph.D, P. Leif Bergsagel, MD, Rafael Fonseca, MD, John Carpten, Jeffrey Trent, Todd R. Golub, MD

Blood (2008) 112 (11): 497.

https://doi.org/10.1182/blood.V112.11.497.497

Published: 2008

Journal Articles

The Multiple Myeloma Research Consortium Genomics Initiative.

Jeffrey Trent, PhD, John Carpten, PhD, Michael Reich, PhD, Ted Liefeld, PhD, Jonathan Keats, PhD, Spyro Mousses, PhD, William Hahn, MD, PhD, Suzanne Trudel, MD, David Siegel, PhD, S. Vincent Rajkumar, MD, Melissa Alsina, MD, Paul Richardson, MD, Kenneth Anderson, MD, Daniel Auclair, PhD, Louise M. Perkins, PhD, Kathy Giusti, Rafael Fonseca, MD, Todd R. Golub, MD

Blood (2007) 110 (11): 2498.

https://doi.org/10.1182/blood.V110.11.2498.2498

Published: 2007

Journal Articles

Genomc-Wide Profiling of Gene Expression and DNA Copy Number Alterations in Multiple Myeloma.

Jonathan Keats, PhD, Mike Chapman, PhD, John Carpten, PhD, Wee-Joo Chng, MD, Angela Baker, PhD, Gregory Ahmann, Suzanne Trudel, MD, David Siegel, MD, PhD, S. Vincent Rajkumar, MD, Melissa Alsina, MD, Paul Richardson, MD, Kenneth Anderson, MD, Daniel Auclair, PhD, Louise M. Perkins, PhD, Jeffrey Trent, PhD, Todd R. Golub, MD, Rafael Fonseca, MD

Blood (2007) 110 (11): 396.

https://doi.org/10.1182/blood.V110.11.396.396

Published: 2007

Journal Articles

PRL3 Is a Mediator of IL6/STAT3 Signaling and Defines a Population of Multiple Myeloma Patients Distinct from Those That Activate NFkB.

Michael Sebag, MD, PhD, Keith Stewart, MD, Chang-Xin Shi, PhD, Yuan-Xiao Zhu, PhD, Wee-Joo Chng, MD, Jonathan Keats, PhD, Rodger E. Tiedemann, MD, PhD, Rafael Fonseca, MD, Marta Chesi, PhD, Peter Leif Bergsagel, MD

Blood (2007) 110 (11): 671.

https://doi.org/10.1182/blood.V110.11.671.671

Published: 2007

Journal Articles

High Resolution Array CGH Identifies TRAF3 as a Novel Tumor Suppressor in Multiple Myeloma.

Blood (2006) 108 (11): 3407.

https://doi.org/10.1182/blood.V108.11.3407.3407

Published: 2006

NARROW

A High-Risk Subgroup Multiple Myeloma Classification Based on the Detection of PR Minor Subclones

Herpesvirus Entry Mediator As a Novel Therapeutic Target in Multiple Myeloma

Prior Immune Effector Cell Therapy, Is Not Associated with an Increased Infectious Risk of Subsequent Bispecific Antibody Therapy for Multiple Myeloma

Identification of novel mutational drivers reveals oncogene dependencies in multiple myeloma

Copper 64–labeled daratumumab as a PET/CT imaging tracer for multiple myeloma

Integrative Analysis of the Genomic Landscape Underlying Multiple Myeloma at Diagnosis: An Mmrf Commpass Analysis

Comprehensive Identification of Fusion Transcripts in Multiple Myeloma: An Mmrf Commpass Analysis

CD33 Is Expressed in a Significant Subset of Multiple Myeloma Patients in the US and May Represent a Viable Therapeutic Target

Adar-Mediated Aberrant a-to-I RNA Editing Is Driven By 1q Amplification and Contributes to Proteasome Inhibitor Resistance in Multiple Myeloma

Biological and Prognostic Impact of Apobec-Induced Mutations in the Spectrum of Plasma Cell Dyscrasias

Transcriptional Plasticity Compensates for Ikaros and Aiolos Proteasomal Degradation and Mediates Resistance to IMiDs in Multiple Myeloma (MM)

TRAF3 and TNFAIP3, Two Negative Regulators of NF-Kb Signaling Pathways, Are Mutated in Waldenström’s Macroglobulinemia

Genomic Complexity and Recurrent Aberration in Multiple Myeloma: Analysis of a Compendium of aCGH and Gene Expression Profiles.

Rearrangements of IER3 Represent a Novel and Recurrent Molecular Abnormality in Myelodysplastic Syndromes (MDS)

Loss of p53 Is a Marker of Progression in Plasma Cell Neoplasias and Is a Negative Prognostic Factor in Relapsed Disease.

Interim Analyses of the MMRC Reference Collection Identifies Recurrent Genomic-Level Events in Multiple Myeloma and Demonstrates That CDKN2C/p18 Deletion Is the Pre-Eminent Copy Number Alteration in Poor Prognosis Disease

The Multiple Myeloma Research Consortium Genomics Initiative.

Genomc-Wide Profiling of Gene Expression and DNA Copy Number Alterations in Multiple Myeloma.

PRL3 Is a Mediator of IL6/STAT3 Signaling and Defines a Population of Multiple Myeloma Patients Distinct from Those That Activate NFkB.

High Resolution Array CGH Identifies TRAF3 as a Novel Tumor Suppressor in Multiple Myeloma.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only